Metagenomi, Inc. (NASDAQ:MGX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Metagenomi, Inc. (NASDAQ:MGX) have received an average rating of “Moderate Buy” from the five brokerages that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $10.00.

Several research analysts have recently commented on the company. Zacks Research raised Metagenomi from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 17th. Wall Street Zen raised shares of Metagenomi from a “sell” rating to a “hold” rating in a research note on Saturday, October 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Metagenomi in a research note on Monday, December 22nd.

Metagenomi Trading Down 3.6%

MGX stock opened at $1.60 on Thursday. The stock’s 50 day simple moving average is $1.69 and its 200 day simple moving average is $2.05. The stock has a market capitalization of $60.08 million, a PE ratio of -0.67 and a beta of 0.50. Metagenomi has a 12-month low of $1.23 and a 12-month high of $3.95.

Metagenomi (NASDAQ:MGX) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.05. The firm had revenue of $8.66 million during the quarter, compared to analysts’ expectations of $7.82 million. Metagenomi had a negative net margin of 287.06% and a negative return on equity of 43.19%. On average, research analysts predict that Metagenomi will post -2.46 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets boosted its position in Metagenomi by 1,840.0% during the third quarter. BNP Paribas Financial Markets now owns 15,171 shares of the company’s stock valued at $36,000 after purchasing an additional 14,389 shares in the last quarter. Bank of America Corp DE raised its holdings in Metagenomi by 508.5% in the third quarter. Bank of America Corp DE now owns 18,766 shares of the company’s stock worth $44,000 after purchasing an additional 15,682 shares in the last quarter. Vanguard Personalized Indexing Management LLC lifted its position in shares of Metagenomi by 53.1% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 21,515 shares of the company’s stock valued at $32,000 after buying an additional 7,458 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Metagenomi in the 3rd quarter valued at about $64,000. Finally, Man Group plc purchased a new position in shares of Metagenomi in the 3rd quarter worth approximately $125,000.

About Metagenomi

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.